Patent ID: 11879009
Assignee: CATALENT PHARMA SOLUTIONS, LLC
Field: Biotechnology (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of inhibiting a target protein and a signaling molecule in a cell, comprising:
contacting the cell with a multifunctional protein molecule comprising at least one decorin molecule having at least 95% sequence identity to SEQ ID NO:7 linked to an antibody molecule selected from the group consisting of bevacizumab, ranibizumab, ipilimumab, atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab under conditions such that at least one activity of the target protein and at least one activity of a signaling protein are inhibited in the cell, wherein the target protein is selected from the group consisting of VEGF-1, PD-1, PD-L1, and CTLA and wherein the signaling protein is selected from the group consisting of Transforming Growth Factor-β (TGF-β), Connective Tissue Growth Factor (CTGF), Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), Hepatocyte Growth Factor Receptor (HGFR), Insulin-like Growth Factor 1 Receptor (IGF-1R), epidermal growth factor receptors (EGFRs), myostatin and C1q.